EvoLiver

Dramatically improving liver cancer outcomes for high risk patients

Transforming liver cancer surveillance

Our initial focus is to transform the surveillance of liver cancer in high-risk populations - the fastest growing cause of cancer related deaths.

For example, 10 million people in the United States and Europe are at high risk of developing liver cancer each year, often due to a pre-existing medical condition such as cirrhosis. These patients are enrolled in surveillance programmes for early liver cancer detection, primarily through ultrasound imaging, which is recommended twice yearly due to the fast progression of liver cancer. 

However, detection rates remain low because ultrasound lacks sufficient sensitivity, particularly in overweight individuals. Additionally, poor adherence to the programme is common, as it requires a separate appointment from routine blood tests and is hindered by the known limitations of ultrasound. 

Clinical performance – MEV01 study

MEV01 is an ongoing multi-centre clinical to evaluate the performance of EvoLiver™ for liver cancer surveillance. 

EvoLiver™ demonstrated 86% early-stage sensitivity and 88% specificity in advanced results (n=374)  presented at AASLD 2024, outperforming current surveillance methods such as the ultrasound and AFP. 

Final results to come in a peer-reviewed publication (2025).

Study Objective

  • Develop EvoLiver™: a pioneering organ-specific blood test based on the cargo of hepatocytes-derived EVs
  • Demonstrate its potential to surpass ultrasound and other alternatives for the surveillance of liver cancer among high risk, cirrhotic population
  • Demonstrate methodological feasibility for other cancer tests

Study Design

  • Up to 800 patient’s samples to be collected mostly prospectively (started in 2022) with some retrospective matching when needed
  • Over 500 patients to be evaluated
  • >300 high risk patients (diagnosed cirrhosis)
  • >150 liver cancer patients (HCC)
  • >5 real-world practices, including hospitals at Imperial College London and UCL
  • >4 clinical investigators

Sample Collection Centers

Coming soon